13-D Filing Shows Euroeyes Owner Letter To Starr Surgical Filed With SEC

This Statement is filed by Joern S. Joergensen, an individual, and EuroEyes Holding AG, an aktiengesellschaft organized in Zurich, Switzerland. The principal business address of Dr. Joergensen is Elbchaussee 454, 22587 Hamburg, Germany. The principal business address of EuroEyes Holding AG is Othmarstrasse 8, 8008 Zurich, Switzerland. Dr. Joergensen is the founder, Chief Executive Officer and Medical Director of EuroEyes Clinical Group, an association of licensed eye clinics and laser eye centers with locations in Germany, Denmark and China. The principal business of EuroEyes Holding AG is the acquisition and management of shares in businesses of all kinds, particularly companies in the ophthalmic laser technology, lens implant and related markets. Dr. Joergensen is the sole owner of EuroEyes Holding AG. Dr. Joergensen is a citizen of Denmark. Each of Dr. Joergensen and EuroEyes Holding AG is referred to herein as a "Reporting Person." Item 3. Source and Amount of Funds or Other Consideration. The source of funds used in effecting the purchases of Common Stock set forth on Schedule A of approximately $574,852 was personal funds of Dr. Joergensen and working capital of EuroEyes Holding AG. Item 4. Purpose of Transaction. The Reporting Persons acquired the Common Stock reported in this Statement for investment purposes. The Reporting Persons may in the future acquire additional shares of Common Stock or dispose of some or all of the shares of Common Stock held by them in open-market transactions or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons may engage in short selling, hedging or similar transactions with respect to the Common Stock, on such terms and at such times as the Reporting Persons may deem advisable. Neither of the Reporting Persons has any present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D, except that Dr. Joergensen has expressed to the Company his interest in serving on its board of directors as a shareholder representative and industry expert. On May 26, 2015, Dr. Joergensen sent a letter to the chairman of the board of directors of the Company relating to his concerns regarding the Company's board of directors and his interest in serving as a member of the board, a copy of which letter is attached as an exhibit to this Statement. The Reporting Persons reserve the right in the future to formulate any plans or proposals, and to take any actions, with respect to their investments in the Company, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D.